Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

Trial Details

NCT ID

NCT06656624

Phase

PHASE2

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• Ribociclib combined with AI±OFS
• physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS

Locations (sample)

• Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

• Patient is an adult female ≥ 18 years old at the time of informed consent.
• ECGO rating 0-2.
• Histologically confirmed recurrent or metastatic breast cancer, including patients initially diagnosed as stage IV or locally advanced inoperable p…
• Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast ca…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.